Chemosensitivity of human melanoma metastases in mouse subrenal capsule assay - Can it predict tumour response to combined cytostatic plus interferon therapy in metastatic melanoma?

Melanoma Research

Volumn 6, Issue 3, 1996, Pages 215-221

  Hahka Kemppinen, M ^a   Muhonen, T ^a   Kangas, L ^b   Pyrhonen S ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b ORION CORPORATION   (Finland)

Author keywords

Chemosensitivity; Chemotherapy; Melanoma; Subrenal capsule assay

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CISPLATIN; DACARBAZINE; ETOPOSIDE; LOMUSTINE; METHOTREXATE; METRONIDAZOLE; PROCARBAZINE; TEGAFUR; TOREMIFENE; VINBLASTINE; VINCRISTINE;

ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CAPSULE; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; DACARBAZINE; FEMALE; HUMANS; INTERFERONS; LOMUSTINE; MALE; MELANOMA; MICE; MICE, INBRED STRAINS; NEOPLASM METASTASIS; SEX CHARACTERISTICS; SUBRENAL CAPSULE ASSAY; VINCRISTINE;

EID: 0029902139     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199606000-00004     Document Type: Article

References (23)

1. Creagan ET, Schaid DJ, Ahmann DL et al. Disseminated malignant melanoma and recombinant interferon: analysis of seven consecutive phase II investigations. J Invest Dermatol 1990; 188-192.
2. York RM, Foltz AT. Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. Cancer 1988; 61: 2183-2186.
3. McLeod GR, Thomson DB, Hersey P. Recombinant interferon alfa-2a in advanced malignant melanoma. A phase I-II study in combination with DTIC. Int J Cancer Suppl 1987; 1: 31-35.
4. Pyrhönen S, Hahka-Kemppinen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1992; 10: 1919-1926.
5. Bogden AE, Kelton DC, Cobb WR et al. A rapid screening method for testing chemotherapeutic agents against human tumor xenografts. In: Houchens DP, Ovejera AA, eds. Proc Symp Use of Athymic (Nude) Mice in Cancer Research. New York: Gustav Fischer, 1978: 231 pp.
6. Bogden AE, Cobb WR, Lepage DJ et al. Chemotherapy responsiveness of human tumors as first transplant generation xenografts in the normal mouse: six-day subrenal capsule assay. Cancer 1981; 48: 10-20.
7. Bogden AE, Haskell PM, LePage DJ et al. Growth of human tumor xenografts implanted under the renal capsule of normal immunocompetent mice. Exp Cell Biol 1979; 47: 281-293.
8. Mäenpää J, Grönroos M, Leppänen M et al. The subrenal capsule assay in mice. Prediction of rat tumor sensitivity to chemotherapy. Cancer 1984; 54: 1530-1534.
9. Slagel DE, DeSimone P, Dillon M et al. Subrenal capsule assay: feasibility of transporting tissues to a central facility for testing. Cancer Treat Rep 1985; 69: 717-718.
10. Kangas L, Perilä M. Clinical praxis and laboratory procedures in subrenal capsule assay (SRCA). Ann Chir Gynaecol 1985; 7-11.
11. Edelstein MB, Fiebig HH, Smink T et al. Comparison between macroscopic and microscopic evaluation of tumour responsiveness using the subrenal capsule assay. Eur J Cancer Clin Oncol 1983; 19: 995-1009.
12. Edelstein MB, Smink T, Ruiter DJ et al. Improvements and limitations of the subrenal capsule assay for determining tumour sensitivity to cytostatic drugs. Eur J Cancer Clin Oncol 1984; 20: 1549-1556.
13. Marek J, Bechyne M. The subrenal capsule assay in immunocompetent mice - the inevitable role of histopathology in assessment of this method as a tool determining tumor sensitivity to cytostatic drugs. Neoplasma 1990; 37: 23-30.
14. Tueni EA, Dumont P, Jacobovitz D et al. Subrenal capsule assay for fresh human tumors in immunocompetent mice; an inappropriate technique for non-small cell lung cancer. Eur J Cancer Clin Oncol 1987; 23: 1163-1167.
15. Kouri M, Pyrhönen S, Kangas L et al. Growth of human colorectal carcinoma implants in the mouse subrenal capsule assay. Ann Chir Gynaecol 1989; 78: 110-114.
16. Dumont P, van der Esch EP, Jabri M et al. Chemosensitivity of human melanoma xenografts in immunocompetent mice and its histological evaluation. Int J Cancer 1984; 33: 447-451.
17. Aamdal S, Fodstad O, Pihl A. Human tumor xenografts transplanted under the renal capsule of conventional mice, growth rates and host immune response. Int J Cancer 1984; 34: 725-730.
18. Griffin TW, Bogden AE, Reich SD et al. Initial clinical trials of the subrenal capsule assay as a predictor of tumor response to chemotherapy. Cancer 1983; 52: 2185-2192.
19. Pyhönen S, Kouri M, Holsti LR et al. Disease stabilization by leukocyte alpha interferon and survival of patients with metastatic melanoma. Oncology 1992; 49: 22-26.
20. Punt CJA, Jansen RLH, Vreugdenhil A et al. Combination chemotherapy together with interferon-alpha (IFN) in metastatic melanoma (MM), a multicenter phase II study. Proc Am Soc Clin Oncol 1995 (Abstr 1301); 14: 411.
21. Nathan FE, Sato T, Berd D et al. Bold + Interferon: Effective systemic therapy for metastatic uveal melanoma. Proc Am Soc Clin Oncol 1995 (Abstr 1297); 14: 410.
22. Muhonen T, Hahka-Kemppinen M, Pakkala S et al. Decreasing CD4/CD8 ratio during prolonged four-drug chemotherapy plus interferon treatment for metastatic melanoma. J Immunother 1994; 15: 67-73.
23. Hernberg M, Muhonen T, Hahka-Kemppinen M et al. The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemo-immunotherapy. J Clin Oncol 1995; in press.